摘要
目的:探讨参芪扶正注射液联合DCF方案化疗应用于胃癌患者的效果。方法:选取医院胃癌患者78例(2018年8月-2019年12月),依据随机数字表法分为对照组和观察组各39例。对照组采用DCF化疗方案治疗,观察组在对照组基础上采用参芪扶正注射液治疗。比较两组疗效、治疗前、治疗4个周期后中医证候积分、肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]水平、血清T淋巴细胞亚群(CD4^(+)、CD3^(+)、CD8^(+))水平、不良反应(恶心呕吐、白细胞减少、黏膜受损、肝肾功能受损、腹泻)发生率。结果:观察组治疗总有效率64.10%高于对照组的41.03%(P<0.05);治疗4个周期后,观察组中医证候积分、CEA、CA19-9、CD8^(+)水平低于对照组,CD4^(+)、CD3^(+)水平高于对照组(P<0.05);观察组恶心呕吐、白细胞减少发生率低于对照组(P<0.05),两组黏膜受损、肝肾功能受损、腹泻发生率比较无明显差异(P>0.05)。结论:参芪扶正注射液联合DCF方案化疗治疗胃癌患者疗效显著,可有效清除癌细胞,增强免疫力,改善临床症状,且安全性高。
Objective:To investigate the effect of Shenqi Fuzheng injection combined with DCF chemotherapy in patients with gastric cancer.Methods:78 patients with gastric cancer in our hospital(from August 2018 to December 2019)were selected and grouped according to random number table,with 39 cases in each group.The control group was treated with DCF chemotherapy,and the observation group was treated with Shenqi Fuzheng injection on the basis of the control group.Compare two groups of curative effect,before and after four cycles of treatment of TCM syndrome integral,tumor markers[carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)]level,serum levels of T lymphocyte subsets(CD4^(+)and CD3^(+),CD8^(+))levels and adverse reactions(nausea and vomiting,leukopenia,mucosa damage,liver and kidney function is damaged,diarrhea).Results:The total effective rate of observation group was 64.10%higher than that of control group(41.03%,P<0.05).After 4 cycles of treatment,the levels of TCM syndrome score,CEA,CA19-9 and CD8+in the observation group were lower than those in the control group,while the levels of CD4^(+)and CD3^(+)were higher than those in the control group(P<0.05).The incidence of nausea,vomiting and leukopenia in the observation group was lower than that in the control group(P<0.05),and there were no significant differences in the incidence of mucosal damage,liver and kidney function damage and diarrhea between the two groups(P>0.05).Conclusion:Shenqi Fuzheng injection combined with DCF regimen chemotherapy in the treatment of gastric cancer patients has significant efficacy,can effectively remove cancer cells,enhance immunity,improve clinical symptoms,and has high safety.
作者
肖学军
杨声坤
Xiao Xuejun;Yang Shengkun(Department of Internal Medicine,People's Hospital of Guangshan County,Guangshan 465450,China)
出处
《亚太传统医药》
2021年第9期58-61,共4页
Asia-Pacific Traditional Medicine
